MedPath

Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography

Phase 1
Conditions
Parkinson's disease
MedDRA version: 21.1Level: LLTClassification code: 10013113Term: Disease Parkinson's Class: 10029205
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Registration Number
CTIS2022-501123-24-00
Lead Sponsor
Centre Hospitalier Universitaire De Toulouse
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
34
Inclusion Criteria

Patients with Parkinson's disease defined according to UKPDSBB criteria, Men and women aged between 40 and 80 years, Patients with stable anti-parkinsonian treatment for at least 4 weeks prior to inclusion, Patients with a MOCA score > 25, Patients with a HADS-D score = 11, Person affiliated or benefiting from a social security scheme., Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion Criteria

Patients treated with second line therapy (deep brain stimulation, pump - duodopa and apokinon), Patients with a history of significant psychiatric pathology according to the investigator, Patients treated with drugs interacting with 5HT1A receptors in the previous 4 weeks (triptan, serotonergic antidepressants), Patients with contraindication to MRI, Patients refusing to be informed of an abnormality discovered during brain imaging, Patients with dyskinesias judged by the investigator to be disabling for imaging, Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision, Pregnant woman, breastfeeding woman

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath